Lip GYH - Search Results

1

Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial.

Essebag V, Proietti R, Birnie DH, Wang J, Douketis J, Coutu B, Parkash R, Lip GYH, Hohnloser SH, Moriarty A, Oldgren J, Connolly SJ, Ezekowitz M, Healey JS. Essebag V, et al. Among authors: lip gyh. Europace. 2017 Oct 1;19(10):1630-1636. doi: 10.1093/europace/euw409. Europace. 2017. PMID: 28339794 Clinical Trial.

2

Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.

Shantsila E, Watson T, Lip GY. Shantsila E, et al. Europace. 2007 Sep;9 Suppl 4:iv37-44. doi: 10.1093/europace/eum169. Europace. 2007. PMID: 17766322 Review.

3

Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association.

Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Kirchhof P, et al. Europace. 2007 Nov;9(11):1006-23. doi: 10.1093/europace/eum191. Epub 2007 Sep 25. Europace. 2007. PMID: 17897925

4

Anticoagulation in atrial fibrillation: the trials and tribulations of keeping within therapeutic range.

Taggar JS, Lip GY. Taggar JS, et al. Curr Med Res Opin. 2008 May;24(5):1455-8. doi: 10.1185/030079908x301875. Epub 2008 Apr 9. Curr Med Res Opin. 2008. PMID: 18402716

5

Defibrillation testing in patients with atrial fibrillation.

Lim HS, Lip GY. Lim HS, et al. Europace. 2009 Aug;11(8):1108-9. doi: 10.1093/europace/eup157. Epub 2009 Jun 23. Europace. 2009. PMID: 19549676 Clinical Trial.

6

Relationship of circulating endothelial progenitor cells to the recurrence of atrial fibrillation after successful conversion and maintenance of sinus rhythm.

Siu CW, Watson T, Lai WH, Lee YK, Chan YH, Ng KM, Lau CP, Lip GY, Tse HF. Siu CW, et al. Europace. 2010 Apr;12(4):517-21. doi: 10.1093/europace/eup382. Epub 2009 Nov 30. Europace. 2010. PMID: 19951966

7

Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.

Khoo CW, Lip GY. Khoo CW, et al. Expert Opin Pharmacother. 2010 Mar;11(4):685-7. doi: 10.1517/14656560903530691. Expert Opin Pharmacother. 2010. PMID: 20105114 Clinical Trial.

8

Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?

Lip GY, Lane DA. Lip GY, et al. Am J Med. 2010 Sep;123(9):785-9. doi: 10.1016/j.amjmed.2010.01.031. Epub 2010 Jul 23. Am J Med. 2010. PMID: 20655037 Review.

9

Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis.

Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Marinigh R, et al. J Am Coll Cardiol. 2010 Sep 7;56(11):827-37. doi: 10.1016/j.jacc.2010.05.028. J Am Coll Cardiol. 2010. PMID: 20813280 Free article. Review.

10

Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments.

Schirmer SH, Baumhäkel M, Neuberger HR, Hohnloser SH, van Gelder IC, Lip GY, Böhm M. Schirmer SH, et al. J Am Coll Cardiol. 2010 Dec 14;56(25):2067-76. doi: 10.1016/j.jacc.2010.09.017. J Am Coll Cardiol. 2010. PMID: 21144965 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,599 results

Search Page

Filters